ReviewTherapeutic advances in gastroenterology2019

The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product.

Joseph E McClellan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.